Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients

[1]  R. Butler,et al.  Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial , 2020, The Lancet. Oncology.

[2]  Yeon-Hee Park,et al.  Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Berchuck,et al.  Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. , 2019, Gynecologic oncology.

[4]  A. Markham.  Alpelisib: First Global Approval , 2019, Drugs.

[5]  E. Sokol,et al.  Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). , 2019, Journal of Clinical Oncology.

[6]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[7]  C. Sotiriou,et al.  Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Baselga,et al.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial , 2019, JAMA oncology.

[9]  M. Lux,et al.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[10]  M. Lux,et al.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[11]  N. Schultz,et al.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Mano,et al.  High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2 , 2018, Clinical Cancer Research.

[13]  P. Suresh.  Breast Cancer Heterogeneity: A focus on Epigenetics and In Vitro 3D Model Systems. , 2018, Cell journal.

[14]  Jiayuan Li,et al.  Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[15]  G. Ciliberto,et al.  Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations , 2018, Journal of experimental & clinical cancer research : CR.

[16]  P. Keegan,et al.  First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.

[17]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[18]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[19]  N. Peled,et al.  Clinical Impact of Hybrid Capture–Based Next‐Generation Sequencing on Changes in Treatment Decisions in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  T. Price,et al.  Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women , 2016, Front. Oncol..

[21]  James X. Sun,et al.  Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). , 2016 .

[22]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[23]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[24]  G. Viale,et al.  The current state of breast cancer classification. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[26]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[27]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[28]  Chen Fang-ma.  The Current State of Breast Cancer Image Examination , 2008 .